Happy to read this news from today.
Go big or go home.
Disclaimer: I own Corcept stock. See sidebar.
Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)
Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)— Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym® (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program. Idis Access Programs enable patients around the world to be prescribed investigational or approved drugs prior to their commercial launch in that country through a regulatory-compliant and ethical channel on a named-patient basis. Corcept, a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, has been offering Korlym in the United States since April 2012 as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.